Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Docebo (DCBO) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Docebo (DCBO) over the last 7 years, with Q3 2025 value amounting to $66.1 million.

  • Docebo's Cash & Equivalents fell 1938.73% to $66.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.1 million, marking a year-over-year decrease of 1938.73%. This contributed to the annual value of $92.5 million for FY2024, which is 2861.71% up from last year.
  • According to the latest figures from Q3 2025, Docebo's Cash & Equivalents is $66.1 million, which was down 1938.73% from $92.5 million recorded in Q2 2025.
  • Docebo's Cash & Equivalents' 5-year high stood at $219.7 million during Q2 2021, with a 5-year trough of $66.1 million in Q3 2025.
  • In the last 5 years, Docebo's Cash & Equivalents had a median value of $212.3 million in 2022 and averaged $158.1 million.
  • As far as peak fluctuations go, Docebo's Cash & Equivalents skyrocketed by 37464.89% in 2021, and later plummeted by 6673.49% in 2023.
  • Over the past 5 years, Docebo's Cash & Equivalents (Quarter) stood at $215.3 million in 2021, then increased by 0.45% to $216.3 million in 2022, then plummeted by 66.73% to $72.0 million in 2023, then grew by 28.62% to $92.5 million in 2024, then decreased by 28.54% to $66.1 million in 2025.
  • Its Cash & Equivalents stands at $66.1 million for Q3 2025, versus $92.5 million for Q2 2025 and $92.5 million for Q1 2025.